Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, that decrease glucose reuptake in the proximal tubules of the nephridium, are one of the most dramatic medicines for type 2 diabetes (T2DM) because of their advantages on renal and cardiovascular functions (13). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.